Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
CA8JhDyc8uR5akFs